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DREWNOWSKI, A., D. D. KRAHN, M. A. DEMITRACK, K. NAIRN AND B. A. GOSNELL. Taste responses and prefer- 
ences for sweet high-fat foods: Evidence for opioid involvement. PHYSIOL BEHAV 51(2) 371-379, 1992.--Preferences and crav- 
ings for sweet high-fat foods observed among obese and bulimic patients may involve the endogenous opioid peptide system. The 
opioid antagonist naloxone, opioid agonist butorphanol, and saline placebo were administered by intravenous infusion to 14 fe- 
male binge eaters and 12 normal-weight controls. Eight of the binge eaters were obese. During infusion, the subjects tasted 20 
sugar/fat mixtures and were allowed to select and consume snack foods of varying sugar and fat content. Naloxone reduced taste 
preferences relative to baseline in both binge eaters and controls. Total caloric intake from snacks was significantly reduced by 
naloxone in binge eaters but not in controls. This reduction was most pronounced for sweet high-fat foods such as cookies or 
chocolate. No consistent effects on taste preferences or food intakes were observed with butorphanol. Endogenous opioid peptides 
may be involved in mediating taste responses and preferences for palatable foods, notably those rich in sugar and fat. 
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ENDOGENOUS opioid peptides are involved in the regulation 
of energy intakes in both humans and rats (15, 58, 63). Several 
studies have shown that opioid antagonists naloxone and naltrex- 
one reduced intakes of laboratory chow in both rats and mice 
(11, 35, 37, 55). Central administration of selective antagonists 
of mu, kappa, and delta receptors also caused reductions in food 
intake of laboratory rats (38, 43, 45). The administration of opi- 
oid agonists had the reverse effect. Such agonists as morphine 
or butorphanol increased food intakes in rats (15, 31, 32, 66). 
Agonists of specific opioid receptors, including mu, kappa, and 
delta, also stimulated food intakes in laboratory rats (31, 33, 38, 
56, 57, 64). 
In clinical studies, the opioid antagonist naloxone reduced 
food consumption of normal-weight and obese subjects (6, 13, 
70, 73) and diminished the size of binge-eating bouts in female 
bulimics (52). Naltrexone also had the effect of reducing food 
consumption in obese humans (7,68). The opposite effects on 
food intake were obtained with the opioid agonist butorphanol. 
In the one study published, injections of butorphanol led to an 
increase in food intake as measured over a 6-h period, an effect 
that was blocked by naloxone (59). 
The effects of opioid peptides on food intake appear to be 
strongest for the most palatable foods. Those animal studies that 
compared the effects of opioid antagonists across diets (3,47) 
found that naloxone and naltrexone caused greater reductions in 
the intake of palatable cafeteria diets as compared to laboratory 
chow. Other studies addressed the effects of opioid peptides on 
the consumption of two palatable dietary ingredients: sugar and 
fat. Naloxone suppressed stress-induced sucrose hyperphagia 
(8,55) and selectively reduced intakes of carbohydrate and fat in 
a dietary self-selection paradigm (49). Conversely, the agonists 
morphine (50) and butorphanol (64) selectively increased fat 
consumption. Some investigators have proposed that the pri- 
mary role of the opioid peptide system is in mediating overeat- 
ing that is associated with exposure to palatable (47) or high-fat 
foods (64). 
Opioid peptides may thus influence energy intakes by medi- 
ating the pleasure response to foods (42). Sensory preferences 
for sweet taste, in particular, appear to be under opioid control. 
It may be that opioid blockade renders palatable foods less re- 
warding (15,63). In studies with rats, opioid antagonists were 
most effective in reducing intakes of palatable sweet liquids such 
as glucose, sucrose or saccharin solutions (36, 41, 45, 54). 
Conversely, morphine enhanced preferences for sweet taste (12) 
and stimulated the intake of sweet solutions. Central administra- 
tion of mu and delta receptor agonists also increased intakes of 
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saccharin solutions in rats (34). Furthermore, mice deficient in 
opioid receptors displayed a reduced preference for the sweet 
taste of saccharin (76). 
Further support for the opioid mediation of food reward is 
provided by clinical reports that oral doses of naltrexone reduced 
pleasantness ratings of glucose solutions and diminished the ac- 
ceptability of food odors (26). Another study showed that opioid 
antagonist nalmefene selectively reduced intake of the most pre- 
ferred foods during a lunch meal (75). However, since most 
previous studies focused on opioids and sweet taste, there are as 
yet no data, either in animals or humans, regarding opioid ef- 
fects on sensory preferences for stimuli containing both sugar 
and fat. It is also unclear whether opioid antagonists would most 
effectively reduce the consumption of foods containing sugar or 
fat, or those foods that are most preferred, regardless of their 
nutrient composition. 
If the effects of opioid antagonists on food intake are sec- 
ondary to a reduction in food palatability, then we should ex- 
pect to see changes in taste preference profiles as well as in food 
consumption. Accordingly, we compared the effects of naloxone 
and butorphanol infusions on taste preferences for a range of 
stimuli containing sugar and fat. Taste responsiveness profiles 
have been used in previous studies to distinguish between rela- 
tive preferences for sugar versus fat among obese, anorectic and 
bulimic patients (18-21). While obese women preferred moder- 
ately sweet but high-fat stimuli (19), anorectic patients liked in- 
tense sweetness but showed an aversion to the oral sensation of 
dietary fat (21). 
The choice of sugar/fat mixtures as sensory stimuli was sug- 
gested by previous research on taste preferences (18-21). Sweet 
high-fat foods are universally regarded as highly palatable and 
are a frequent target of food cravings. Specific cravings for such 
foods as chocolate, cookies or ice cream have been reported by 
obese patients (74), by patients with seasonal affective disorder 
(65), and following treatment with antidepressants (27,61). Al- 
though such cravings have been termed "carbohydrate cravings" 
by some investigators (74), the fact is that chocolate, cookies 
and ice cream are palatable sweet mixtures of two key ingredi- 
ents: sugar and fat (16). 
Clinical observations and anecdotal reports suggest further 
that the compulsive eating bouts in bulimia nervosa often involve 
the same dessert-type foods, rich in both sugar and fat (17,51). 
Given the connection to food cravings, we hypothesized that the 
most pronounced effects of opioid peptides would be obtained 
for palatable foods that are mixtures of sugar and fat. 
Taste preference profiles may be predictive of food choice 
and actual food consumption. To examine the effects of nalox- 
one and butorphanol infusions on caloric intakes, we provided 
the subjects with a choice of palatable snack foods of varying 
sugar and fat content. If opioid effects on food intake are nutri- 
ent specific, then the consumption of foods rich in sugar or fat 
should be affected the most. Conversely, if opioid antagonists 
reduce the reward value of the most preferred foods, most pro- 
nounced effects should be obtained for the most highly rated 
foods, independent of their nutrient composition (75). 
While opioid mechanisms may not be central to normal food 
intake, they may be important in mediating binge-eating epi- 
sodes among susceptible individuals. In past clinical studies, ab- 
normal opioid peptide levels have been observed among both 
obese and eating-disordered women characterized by a pattern 
of binge eating (30,40). Accordingly, we examined the effects 
of naloxone and butorphanol on taste preferences and food con- 
sumption patterns in compulsive binge eaters and in normal- 
weight female controls. Our hypothesis was that the effects of 
opioid peptides on taste preferences and food choice would be 
TABLE I 
SUMMARY OF SUBJECT CHARACTERISTR ~ 
Binge Eaters !'~mtr¢~l~ 
( n =  14~ in= I 
Age (years) 26.3 (2.0) ~I~:~ ~2~! 
Height (cm) 160.4 (I .2) lf,75 i1.5~ 
Weight (kg) 80.0 (6.2) 63,7 ~ 1.8) 
BMI (kg/m 2) 30.9 (2.2) 22.7 ~0,6) 
Restraint score 23.4 ( 1.1 ) i 2. ! ~ 1 1 } 
Data are means and SEMs (in parentheses). 
more pronounced among women with eating disorders than 
among female controls. 
METHOD 
Subjects 
Women subjects, 18 to 40 years old, were recruited through 
advertisements placed in community newspapers. Fourteen of the 
subjects were self-reported binge eaters. Confirmatory diagnosis 
of binge eating was made during a clinical interview based on 
responses to questions regarding DSM-III-R bulimia nervosa (2) 
contained in the Diagnostic Survey of Eating Disorders (39) and 
the structured clinical interview (SCID). Twelve out of 14 binge 
eaters fulfilled DSM-III-R criteria for bulimia nervosa, while the 
remaining 2 reported frequent binging without purging. None of 
the 14 binge eaters was a patient at the University Hospital Eat- 
ing Disorders Clinic and none had a prior history of anorexia 
nervosa. However, 8 binge eaters had prior histories of depres- 
sion and one had a history of chemical dependency in remis- 
sion. Eight out of 14 binge eaters were obese. Obesity was 
defined as body mass index (BMI=kg/m 2) in excess of 28.0. 
Mean weight for the group was 80.0 kg. Physical examination 
and laboratory data revealed no evidence of abnormalities requir- 
ing exclusion such as gastrointestinal or endocrine dysfunction. 
None of the subjects was on medication. All binge eaters re- 
ported regular menstrual cycles. 
Control subjects (N= 12), also recruited through advertise- 
ments, were of normal weight and had no history of binge eat- 
ing. These subjects were between 90 and 110% of median 
weight for height from NHANES II data (1), were not currently 
dieting to lose weight, and had no prior history of an eating dis- 
order as determined by the structured clinical interview (SCID). 
Physical examination and laboratory data were routine. The sub- 
jects had regular menstrual periods and were not on medication. 
Both binge-eating and normal women were tested in the follicu- 
lar phase of their menstrual cycle, with all tests completed in 
the first 10 days of the cycle. All subjects signed the informed 
consent form and all protocols had been approved by IRB at the 
University of Michigan. The subjects were compensated for 
completing the study. Subject characteristics are summarized in 
Table 1. 
Drugs 
The drugs were opioid antagonist natoxone, opioid agonist 
butorphanol tartrate, and saline placebo. Naloxone, a shortqast- 
ing opioid antagonist, was administered as a 6-mg bolus fol- 
lowed by 0,1-mg/kg/h intravenous drip for 2.5 h. The same dose 
of naloxone had been used to decrease size of binges in bulimic 
women (52). Butorphanol, a synthetic mixed agonist/antagonist, 
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was administered as a 1-1xg/kg bolus followed by IV saline drip. 
This dose had been shown to increase food intake in one previ- 
ous study (59). Apart from causing sleepiness in one subject, 
this dose had no observable side effects. Since drug doses were 
calculated per kilogram of body weight, obese binge eaters re- 
ceived higher absolute doses of the two drugs than did normal- 
weight binge eaters or normal-weight controls. It may be that 
body weight per se affects the response to opioid manipulations. 
However, data analyses showed that there was no difference in 
drug effects on food intake between the present samples of obese 
(n = 8) and normal-weight (n = 6) binge eaters. All binge eaters 
(n = 14) were therefore treated as a single group. 
Sensory Stimuli 
Sensory stimuli were 20 samples of sweetened commercial 
dairy products of varying sugar and fat content. These included 
whole milk (3.5% fat), half and half (10% fat), light cream 
(20% fat) and heavy cream (36.0% fat), sweetened with 2, 4, 8, 
16 and 32% sucrose in a 4 × 5 factorial design. Sucrose levels 
were set weight by weight (wt./wt.) rather than weight by vol- 
ume (wt./vol.) in order to provide a direct means of comparison 
to previous studies on liquid and solid foods (24). The stimuli, 
chilled to 5°C, were presented to subjects in 10-ml plastic cups 
and in a random order for taste and hedonic evaluations. The 
subjects tasted each sample and rated it on four 9-point category 
scales. For the scaling of acceptability or hedonic preference, the 
subjects used a fully anchored 9-point hedonic preference scale 
(20), ranging from "dislike extremely" to "l ike extremely." 
For the scaling of sweetness, creaminess and fat content, the 
subjects used three unipolar category scales, with each quality 
ranging from "absent"  to "ex t reme."  Following previous pro- 
cedures, the subjects were instructed to taste each stimulus, ex- 
pectorate, and rinse their mouths with water between samples. 
Food Stimuli 
Food stimuli were 16 common snack foods containing differ- 
ent amounts of sugar and fat (62). Their caloric density and nu- 
trient composition as percent calories are shown in Table 2. 
Foods in Category 1 were low in both sugar and fat. Category 2 
foods were low in sugar but high in fat. Category 3 foods were 
sweet but low in fat. Category 4 foods were high in both sugar 
and fat. 
On a day prior to testing, the subjects indicated how much 
they liked each of the 16 foods using a food preference check- 
list and a 9-point category scale. Mean hedonic ratings for the 
16 foods are shown in Table 2, averaged across the entire sub- 
ject population (n = 26). During drug infusion, each subject was 
presented with those 8 foods (2 from each category), which she 
herself had rated most highly. Thus each subject was offered 
those foods she regarded as most palatable, and no subject was 
presented with foods she disliked. The foods were presented in 
100-kcal portions. The subjects were told that they could eat any 
food on the tray in any order they liked. If they ate the entire 
100-kcal portion, another portion would be provided by the ex- 
perimenter. 
Internal States 
Acute changes in perceived hunger, fullness and nausea were 
assessed every 30 min during drug infusion. The subjects rated 
their status using 5-point category scales: 5-inch lines separated 
into 1-inch intervals and anchored at each end with statements 
ranging from "not  at all " to "extremely . "  
Experimental Protocol 
The study followed a double-blind within-subjects design. 
Each subject received all three drug or placebo infusions, ad- 
TABLE 2 
FOODS AVAILABLE FOR CONSUMPTION: 
A SUMMARY OF FOOD CHOICES 
Hedonic kcal per Macronutrient 
Rating Portion Content (kcal) 
Category 1: low sugar/low fat CHO PRO Fat 
Popcorn 7.19 101 79 12 9 
Saltines 6.19 94 72 9 19 
Breadsticks 5.69 99 79 12 9 
Pretzels 6.65 109 84 7 8 
Category 2: low sugar/high fat 
Fritos 5.69 98 41 4 55 
Cream cheese + saltines 4.50 101 20 8 72 
Potato chips 6.57 101 38 4 58 
Lorna Doones 6.16 96 58 4 38 
Category 3: high sugar/low fat 
Jelly beans 4.84 100 100 0 0 
Marshmallows 4.84 99 97 3 0 
Jello 5.27 100 100 0 0 
Jelly + saltines 4.42 109 93 2 5 
Category 4: high sugar/high fat 
Chocolate chip cookies 7.73 109 55 4 41 
Snickers bar 6.73 105 48 10 43 
M&M candies 7.77 100 54 5 41 
Oreo cookies 6.61 96 58 4 38 
ministered in a random order and at least two days apart. On 
each infusion day, the subjects presented to the Clinical Re- 
search Center at 8 a.m. after fasting since 10 p.m. the previous 
night. An intravenous catheter was placed in the arm vein, and 
saline infusion was started at that time. At 8:30 a.m., the sub- 
jects first rated their hunger, fullness and nausea using category 
scales. The subjects were then presented with the fast set of 20 
taste stimuli for sensory and hedonic evaluations (pretreatment 
baseline). Drug infusions began at 9 a.m. The second set of taste 
responses was obtained after 1 h of infusion (posttreatment). 
Ratings of internal states were repeated every 30 minutes during 
the infusion. At 10:30 a.m., the subjects were presented with 8 
foods on a tray and were allowed to select and consume the 
foods ad lib for a period of 1 h. The trays were removed and 
drug infusion was stopped at 11:30 a.m. 
Data Analyses 
Hedonic responses and ratings of perceived sweetness, cream- 
iness and fat content of taste stimuli were first analyzed using a 
five-way BMDP ANOVA for repeated measures. Subject group- 
ing (binge eaters versus controls) was a between-subjects vari- 
able, while drug type (butorphanol, naloxone or saline), drug 
treatment (pre- vs. posttreatment), and fat and sugar content of 
sensory stimuli all served as within-subjects variables. Separate 
analyses of variance were also conducted for each drug in turn. 
Additional analyses of variance were conducted to compare he- 
donic preferences profiles of binge eaters and normal-weight 
controls in the baseline (i.e., pretreatment) condition. 
Analyses of variance followed by Dunnett's t-tests were used 
to compare caloric intakes between the drug and the saline con- 
ditions. Anovas were conducted for the total calories consumed 
during the allowed 1-h period, and for calories by food category 
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FIG. 1. Perceived sweetness ratings for binge eaters (top) and controls 
(bottom) as a function of sucrose levels before and after drug infusion. 
The data are shown separately for the three drug conditions. 
(1 through 4) and by macronutrient content (carbohydrate, pro- 
tein and fat). Comparisons between binge eaters and controls 
were made by t-tests. 
To determine whether opioid effects varied with nutrient 
composition or the palatability of the food, all snacks were ar- 
ranged in rank order of hedonic preference. Spearman corre- 
lation coefficients were used to link preferences with the magni- 
tude of drug effects. Analyses of internal states (hunger, full- 
ness, nausea) were made using BMDP ANOVA for repeated 




All subjects correctly rated increasing sweetness of taste 
stimuli. As in past studies (18-21), sweetness intensity ratings 
rose monotonically with increasing stimulus sucrose levels. Fig- 
ure 1 shows sweetness intensity ratings of binge eaters (top 
panel) and controls (bottom panel) as a function of sucrose lev- 
els, separately for each drug type, before and after drug infu- 
sion. A five-way analysis of variance showed significant main 
effects of sugar, F(4,96)=303.2, p<0.01, and fat, F(3,72)= 
7.16, p<0.01. Sweetness intensity ratings did not differ between 
binge eaters and controls (main effect of group: F< 1, ns). Simi- 
larly, sweetness intensity ratings were not affected by drug 
treatment, F(1,24)-- 2.20, ns. Separate ANOVAs of sweetness 
ratings conducted for each drug type revealed significant main 
effects of sugar, fat, or both, but no main effect of diagnostic 
group and no main effect of drug treatment. 
Sensory assessments of stimulus creaminess also rose with 
increasing stimulus fat content. Figure 2 shows creaminess rat- 
ings of binge eaters (top panel) and controls (bottom panel) as a 
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FIG. 2. Perceived creaminess ratings for binge eaters (top) and controls 
(bottom) as a function of sucrose levels before and after drug infusion. 
The data are shown separately for the three drug conditions. 
function of stimulus fat content, separately for each drug, before 
and after drug infusion. Five-way analysis of variance showed 
significant main effects of fat, F(3,72)=93.51, p<0.01, and 
sugar, F(4,96)=26.85, p<0.01. However, no main effects of 
subject group, drug type or drug treatment were observed. Sepa- 
rate ANOVAs conducted for each drug type in turn showed the 
expected significant main effects of fat and sugar, but no main 
effect of subject group or drug treatment. 
Similar results were obtained for sensory assessments of fat 
content. The main effects of fat, F(3,72)= 110.18, p<0.01, and 
sugar, F(4,96)= 10.79, p<0.01, were both significant. How- 
ever, no main effects of group, drug type or drug treatment were 
observed. Separate ANOVAs conducted for each drug type 
showed significant main effects of both fat and sugar, but no 
main effect of subject group and no main effect of drug treat- 
ment. Thus drugs had no effect on sensory functioning and did 
not affect the subjects' perception of the sweetness or fat con- 
tent of taste stimuli. 
Taste Preference Profiles 
Hedonic response profiles of binge eaters and controls in the 
baseline (i.e., pretreatment) condition are summarized in Fig. 3. 
Analysis of baseline data showed significant main effects of 
sugar, F(4,96)=6.96, p<0.01, and fat, F(3,72)= 7.74, p<O.01. 
Binge eaters showed higher preference ratings for more intensely 
sweet solutions: the sugar by group interaction was significant, 
F(4,96) = 2.64, p<0.05. In contrast, binge eaters did not differ 
from controls in their preferences for stimulus fat; the fat by 
group interaction was not significant, F(3,72)= 1.22, ns. 
As in previous studies (18-21), hedonic preference ratings 
followed an inverted-U shape, with peak preferences obtained at 
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FIG. 3. Hedonic preference profiles of binge eaters and controls at base- 
line as a function of stimulus sucrose (left) and fat content (right panel). 
an optimum point or breakpoint. For normal controls, this break- 
point was observed at 8% sugar and 20% fat. Binge eaters 
tended to prefer stimuli that were more intensely sweet (16% 
sucrose), again in agreement with previous results (17,18). 
Opioid Effects on Taste Preferences 
Naloxone infusions significantly reduced hedonic preferences 
for the sugar/fat mixtures. As shown in Fig. 4, preference rat- 
ings declined as a function of both sugar and fat content. This 
effect was observed equally for binge eaters and for controls. In 
contrast, the effects of butorphanol were more complex. Butor- 
phanol appeared to reduce hedonic preferences in binge eaters 
but to increase them in controls. Saline placebo had no effects. 
Five-way analysis of variance showed a significant drug type by 
treatment (pre-post) interaction, F(1,24)=4.83, p<0.01, con- 
firming that different drugs had distinct effects on taste prefer- 
ences. The finding that binge eaters and controls differed in their 
response to butorphanol was confirmed by a significant group 
by drug type by treatment interaction, F(2,48)= 3.45, p<0.05. 
As expected, main effects of sugar, F(3,72) = 6.15, p<0.01, and 
fat, F(4,96)= 6.22, p<0.01, were significant as well. 
Analyses of preference scores were also conducted for each 
drug in turn. Analyses of naloxone data showed a significant 
main effect of drug treatment, F(1,24)=6.43, p<0.01, but no 
group by treatment interaction. These results suggest that taste 
preferences of binge eaters and controls were equally affected 
by naloxone. As expected, the main effect of sugar was signifi- 
cant as well, F(4,96)=4.00, p<0.01. 
Analyses of butorphanol data showed no main effect of drug 
treatment on taste preferences. The expected group by treatment 
interaction was only marginal, F(1,24)=3.89, 0.05<p<0.10. 
Main effects of sugar, F(4,96) = 5.29, p<0.01, and fat, F(3,72) = 
6.20, p<0.01, were both significant. Data analyses for saline 
placebo showed no main effects of either group or drug treat- 
ment. Only the main effects of sugar, F(4,96)= 5.54, p<0.01, 
and fat, F(3,72) = 5.75, p<0.01, were significant. 
Additional ANOVAs for each drug were conducted sepa- 
rately for bingc eaters and controls. For binge eaters, the main 
effect of drug treatment was obtained only for naloxone, F(I, 13) = 
7.71, p<0.05, but not for saline or butorphanol. There was also 
a significant treatment by fat by sugar interaction, F(12,156)= 
1.86, p<0.05. For controls, main drug treatment effect was ob- 
tained only for naloxone, F(1,11) = 3.98, p<0.05, one-tailed, 
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FIG. 4. Hedonic preference profiles of binge eaters (top) and controls 
(bottom) as a function of drug infusion. The data are shown as a func- 
tion of stimulus sucrose (left) and fat content (right panel). 
Opioids and Food Consumption 
Food consumption data are summarized in Table 3. Control 
women consumed a mean of 505 kcal/h when infused with sa- 
line placebo. The largest proportion of calories derived from 
high-fat foods in Category 2 and from sweet high-fat foods in 
Category 4. Although naloxone reduced snack consumption (397 
vs. 505 kcal), the difference in calories was not statistically sig- 
nificant, Dunnett's t(3,22)= 1.96, 0.10>p>0.05. Butorphanol 
had no effects on food consumption. 
Binge eaters consumed somewhat more calories during the 
saline condition than did controls (694 vs. 505 kcal), but the 
difference was not statistically significant, t(24)= 1.31, p>0.05. 
Most calories were derived from high-fat foods in Category 2 
and sweet high-fat foods in Category 4. Naloxone infusions sig- 
nificantly reduced total caloric intakes relative to the saline con- 
dition, Dunnett's t(3,26) = 3.07, p<0.01. The reduction in calories 
was significant only for sweet high-fat foods in Category 4, 
Dunnett's t(3,26)= 3.24, p<0.01. Butorphanol again had no ef- 
fects on the binge eaters' food consumption. 
Nutrient composition of foods consumed by binge eaters and 
controls is summarized in Table 4. Naloxone-mediated reduction 
in caloric intake did not appear to be macronutrient specific. In- 
takes of protein, carbohydrate and fat were all significantly re- 
duced in binge eaters. For normal controls, only fat intake was 
significantly reduced, when tested with a one-tailed test, Dun- 
nett's t(3,22) = 2.29, p<0.05. 
The effects of naloxone on the consumption of individual 
foods are shown in Fig. 5. Caloric intake of each food under 
naloxone is expressed as percent of caloric intake for that food 
in the saline placebo condition. The average percent change for 
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TABLE 3 
SUMMARY OF FOOD CONSUMPTION PATTERNS FOR BINGE EATERS 
AND CONTROLS AS A FUNCTION OF DRUG INFUSION 
Butorphanol Naloxone Saline 
Binge eaters 
Category 1: low sugar/low fat 
Category 2: low sugar/high fat 
Category 3: high sugar/low fat 
Category 4: high sugar/high fat 
Total (kcal/h) 
Normal controls 
Category 1: low sugar/low fat 
Category 2: low sugar/high fat 
Category 3: high sugar/low fat 
Category 4: high sugar/high fat 
Total (kcal/h) 
128 (39) 87 (33) 95 (20) 
157 (52) 144 (53) 226 (56) 
70 (20) 65 (16) 112 (26) 
161 (49) 121 (51)* 261 (69) 
518 (103) 417(101)* 694 (121) 
87 (20) 107 (22) 105 (18) 
193 (50) 140(36) 195 (38) 
72 (27) 49 (17) 55 (17) 
143 (30) 102 (33) 143 (30) 
496 (83) 397 (76) 505 (66) 
Data are means (kcal/h) and SEMs. 
*p<0.05; Dunnett's t-test. 
nonsweet, nonfat foods (Category 1) was - 4 % ,  that is, a small 
net increase. In contrast, net reduction in calories was 29% for 
high-fat foods (Category 2); 39% for sweet foods (Category 3); 
and 54% for sweet high-fat foods (Category 4). 
There was no significant correlation between the magnitude 
of naloxone effects and the foods' palatability ratings as judged 
by the subjects (r = .  10; ns). Intake of some of the most highly 
rated foods (e.g., popcorn) was not altered by naloxone. 
Internal States 
Measures of internal states obtained at 30-minute intervals 
during drug infusion are summarized in Fig. 6. As expected, 
hunger decreased and fullness increased following the consump- 
tion of snack foods. Anova for repeated measures showed sig- 
nificant main effects of time for both hunger, F(5,120)= 32.63, 
p<0.01,  and fullness ratings, F(5,120) = 47.06, p<0.01.  In con- 
trast, ratings of nausea did not change with time, F(5,120)= 
1.42, ns. Hunger and fullness ratings for binge eaters did not 
change as much following snack ingestion, reflecting potential 
difficulties in interoceptive awareness. 
TABLE 4 
MACRONUTRIENT CONTENT OF FOODS CONSUMED BY BINGE EATERS 
AND CONTROLS AS A FUNCTION OF DRUG INFUSION 
Butorphanol Naloxone Saline 
Binge eaters 
Carbohydrate 320 (57) 253 (52)* 422 (69) 
Protein 29 (6) 22 (5)* 34 (7) 
Fat 169 (46) 142 (48)* 237 (51) 
Normal controls 
Carbohydrate 293 (54) 239 (45) 292 (35) 
Protein 25 (4) 22 (4) 27 (4) 
Fat 178 (35) 136 (32)t 186 (33) 
Data are means (kcal/h) and SEMs. 
*p<0.05; Dunnett's test, two-tailed, tone-tailed. 
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FIG. 5. Mean intakes of different foods by naloxone-treated subjects 
(n = 26) expressed as percentage of intakes under saline placebo. 
Drug infusions did not alter hunger or fullness ratings. The 
effects of naloxone or butorphanol on the perception of hunger 
or fullness were not significant. The overall effect of drug con- 
dition on ratings of nausea was significant, F(2,48) = 6.12, p<0.01.  
When controls and binge eaters were analysed separately, the 
effect of drug condition was significant only for binge eaters, 
F(2,26) = 5.65, p<0 .0  I, but not for controls, F(2,22) = 2.30, ns. 
DISCUSSION 
Opioid-mediated reduction in food intake may be secondary 
to changes in taste preferences and the reward value of food. 
The opioid antagonist naloxone significantly reduced taste pref- 
erences for sugar/fat sensory stimuli in female binge eaters and 
in controls. Naloxone also significantly reduced the consumption 
of sweet high-fat foods in binge eaters, though not in controls. 
Strongest effects of naloxone in reducing caloric intake were ob- 
tained for the food group composed of M&M candies, Snickers 
bars, and Oreo and chocolate chip cookies (Category 4). As 
noted previously, such foods are among the most common tar- 
gets of food cravings, and figure prominently in reports of eat- 
ing binges in obesity and bulimia nervosa (22,71). Hunger and 
fullness ratings were not affected by naloxone infusions, arguing 
against the notion that opioid antagonists modulate hunger and 
satiety as applied to normal feeding. 
Taste responsiveness profiles are a direct measure of food 
palatability and have been used to predict food preferences and 
food consumption (60). However, our data do not wholly sup- 
port the hypothesis that the effects of naloxone should be maxi- 
mal for the most preferred foods, regardless of their nutrient 
composition. Although cookies and chocolate (both Category 4 
foods) were highly preferred, the subjects gave almost equally 
high ratings to saltines and popcorn. While the consumption of 
Category 4 foods was significantly reduced by naloxone, the 
consumption of popcorn was, on the contrary, increased. In 
contrast to a study by Yeomans (75), our data failed to show a 
significant correlation between naloxone-induced reduction in 
food intake and self-reported food preferences, also established 
using a standard food checklist. However, it should be noted that 
the snack foods in our study were specifically selected for their 
high palatability, and the subjects were not offered any of the 
foods they disliked. As a result, our study design did not allow 
for a powerful contrast between preferred and nonpreferr~ foods. 
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FIG. 6. Ratings of internal states: hunger, fullness and nausea as rated by subjects at 8:30 a.m. and at 
30-min intervals during drug infusions. The data are shown for binge eaters (right panels) and controls (left 
panels). 
Opioid effects did not appear to be macronutrient specific. In 
contrast to some animal studies (49,50), naloxone did not selec- 
tively reduce the intake of any one macronutrient. The reduction 
in caloric intake in binge eaters was associated with significant 
reductions in calories from carbohydrate, protein, and fat. Only 
the reduction in fat calories was significant for control women, 
most likely because foods in the affected Categories 2 and 4 
were rich in fat. 
The present data suggest that some palatable foods are more 
sensitive to opioid antagonism than are less-preferred foods. Al- 
though several past studies have demonstrated significant opioid 
effects on "normal" foods such as sandwiches, the present study 
indicates that foods rich in sugar and fat may be affected the 
most. The difference is most likely that of degree rather than 
specific food type. However, it should also be noted that all 
foods in Category 4 contained chocolate. Chocolate cravings 
have been observed in obesity and eating disorders (51,74), sea- 
sonal affective disorder (SAD) (65), as a function of the men- 
strual cycle (69) and in the course of antidepressant treatment 
(61). The potential connection between opioid peptides and 
preferences for chocolate is the subject of continuing investi- 
gation. 
If opioid antagonists primarily reduce that part of overeating 
that is due to palatable foods, then most pronounced effects of 
naloxone might be expected among those subjects who are most 
vulnerable to challenge with palatable diets. Both obese and 
normal-weight binge eaters report a pattern of compulsive over- 
eating that can be triggered by palatable foods. Our data showed 
that the naloxone more effectively reduced food intakes among 
binge eaters as compared to normal-weight controls. Conse- 
quently, the main therapeutic value of opioid antagonists may 
be in reducing binge-eating episodes and not in the long-term 
control of body weight. 
The present observations may thus help explain why treat- 
ment with opioid antagonists has failed to induce weight loss in 
many obese individuals. Clinical studies have shown that nalox- 
one reduced food intakes of obese and normal-weight subjects 
(6, 13, 52). Chronic treatment with naltrexone, a longer-lasting 
opioid antagonist, also suppressed food intakes of obese patients 
during a lunch meal (68). However, body weights were for the 
most part unaffected by chronic naltrexone treatments (7, 46, 
53). Given their undesirable effects on liver function, high doses 
of opioid antagonists are not currently viewed as potential ther- 
apy adjuncts for weight reduction (7,53). 
Contrary to our predictions, butorphanol had no significant 
effects on food consumption. In one previous study (52), butor- 
phanol injections increased the consumption of ham, jelly and 
peanut butter sandwiches over a 6-h time period. In our study, 
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butorphanol had no effect on food consumption; however, data 
were collected only over a 1-h period. Although butorphanol in- 
creased taste preferences of control women, it reduced taste 
preferences of bulimics, though not significantly so. However, 
it should be noted that butorphanol has a mixed agonist/antago- 
nist activity. If the opioid peptide system in binge eaters is ab- 
normal, the antagonist qualities of butorphanol might become 
more apparent than they would be in controls. Specifically, if 
compulsive eating of preferred foods by binge eaters is more 
"opioid mediated,"  then these subjects might be more sensitive 
to the opioid antagonist qualities of butorphanol. Still, it is un- 
clear why butorphanol failed to stimulate intake of preferred 
foods at a dose equal to that used in a previous study (52). It 
may be that other opioid agonists, including delta and mu recep- 
tor agonists, are likely to be more successful in mediating palat- 
ability-induced food consumption. 
The present results suggest that abnormalities in the endoge- 
nous opioid peptide system may be linked to elevated sensory 
preferences for sugar/fat mixtures and compulsive overeating of 
sweet high-fat foods. Abnormal opioid peptide levels have been 
observed in obese rats (48), and among obese and anorectic 
women (30,40). Additional studies suggest that the consumption 
of palatable foods may in turn influence the endogenous opioid 
peptide system, it is interesting to note that most dictm5 m,tnll; 
ulations of endogenous opioid peptide levels have empioycd 
preparations of fat, sugar, or both. In one study ~25i, the ~,,n 
sumption of chocolate milk or chocolate candy b) rals ~aused 
increased release of beta-endorphin. In other studies, infusions 
of sucrose solutions or fat emulsions increased analgesia thresh- 
olds in infant rats, suggesting an increase in opioid release 
(10,67). These effects may be linked to the acquisition oi fi~od 
preferences: some investigators have proposed that opioid release 
might sustain ingestive behavior and lead to development ~f 
sweet preferences (9). Similar findings have been obtained in 
human studies (28,29). 
Obvious parallels have also been drawn between binge eating 
and drug addiction, since both behavioral syndromes involve in- 
tense cravings and loss of control. It may be that the ~ame 
physiological mechanisms are involved in mediating food crav- 
ings and drug reward. Both clinical observations and anecdotal 
reports indicate that sweet cravings are often associated with 
opiate addiction (72), while opiate withdrawal is sometimes 
eased by sweets (54). The present study provides preliminary 
evidence in favor of the hypothesis that food cravings in obesity 
and eating disorders may be mediated by the endogenous opioid 
peptide system. 
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